

Patrick Yung Wen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2765772/publications.pdf>

Version: 2024-02-01

32
papers

781
citations

1040056

9
h-index

752698

20
g-index

32
all docs

32
docs citations

32
times ranked

1565
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. <i>Neuro-Oncology</i> , 2015, 17, 116-121.	1.2	207
2	Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	170
3	Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector. <i>Nature Medicine</i> , 1997, 3, 1145-1149.	30.7	158
4	Melanoma central nervous system metastases: current approaches, challenges, and opportunities. <i>Pigment Cell and Melanoma Research</i> , 2016, 29, 627-642.	3.3	102
5	Expression profiles of 151 pediatric low-grade gliomas reveal molecular differences associated with location and histological subtype. <i>Neuro-Oncology</i> , 2015, 17, 1486-1496.	1.2	39
6	Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib/II, open-label, multicentre, randomised study. <i>ESMO Open</i> , 2020, 5, e000672.	4.5	22
7	Gender and sex disparity in cancer trials. <i>ESMO Open</i> , 2020, 5, e000773.	4.5	21
8	Imaging Criteria in Neuro-oncology. <i>Seminars in Neurology</i> , 2018, 38, 024-031.	1.4	17
9	Phase I, open-label, multicentre study of buparlisib in combination with temozolomide or with concomitant radiation therapy and temozolomide in patients with newly diagnosed glioblastoma. <i>ESMO Open</i> , 2020, 5, e000673.	4.5	16
10	Congress of Neurological Surgeons systematic review and evidence-based guidelines update on the role of cytotoxic chemotherapy and other cytotoxic therapies in the management of progressive glioblastoma in adults. <i>Journal of Neuro-Oncology</i> , 2022, 158, 225-253.	2.9	7
11	Congress of Neurological Surgeons systematic review and evidence-based guidelines update on the role of targeted therapies and immunotherapies in the management of progressive glioblastoma. <i>Journal of Neuro-Oncology</i> , 2022, 158, 265-321.	2.9	5
12	CTNI-05. PRELIMINARY RESULTS OF THE NERATINIB ARM IN THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT): A PHASE II PLATFORM TRIAL USING BAYESIAN ADAPTIVE RANDOMIZATION. <i>Neuro-Oncology</i> , 2021, 23, vi59-vi59.	1.2	4
13	RARE-09. EFFICACY AND SAFETY OF DABRAFENIB + TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600Eâ€“MUTATED HIGH-GRADE GLIOMA (HGG). <i>Neuro-Oncology</i> , 2018, 20, vi238-vi238.	1.2	3
14	CTNI-18. PHASE I AND PRELIMINARY PHASE 0 RESULTS OF ABTC 1801: A MULTI-ARM CLINICAL TRIAL OF THE PARP INHIBITOR PAMIPARIB (BGB290) WITH VERY LOW DOSE METRONOMIC TEMOZOLOMIDE IN RECURRENT IDH MUTANT GLIOMAS. <i>Neuro-Oncology</i> , 2021, 23, vi63-vi63.	1.2	3
15	CTIM-06. CLINICAL EFFICACY AND BIOMARKER ASSESSMENT OF VT1021, A CD36/CD47 DUAL-TARGETING AGENT, IN RECURRENT GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2021, 23, vi50-vi50.	1.2	2
16	BMET-26PHASE 2 STUDY OF VB-111, AN ANTI-CANCER GENE THERAPY, AS MONOTHERAPY FOLLOWED BY COMBINATION OF VB-111 WITH BEVACIZUMAB, IN PATIENTS WITH RECURRENT GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2015, 17, v50.4-v51.	1.2	1
17	ATIM-12. NEOADJUVANT ANTI-PD-1 IMMUNOTHERAPY PROMOTES INTRATUMORAL AND SYSTEMIC IMMUNE RESPONSES IN RECURRENT GLIOBLASTOMA: AN IVY CONSORTIUM TRIAL. <i>Neuro-Oncology</i> , 2018, 20, vi3-vi3.	1.2	1
18	NIMG-01. INTEROBSERVER VARIABILITY OF THE REVISED IMAGING SCORECARD FOR LEPTOMENINGEAL METASTASIS: A JOINT EORTC BRAIN TUMOR GROUP AND RANO EFFORT. <i>Neuro-Oncology</i> , 2021, 23, vi126-vi127.	1.2	1

#	ARTICLE	IF	CITATIONS
19	CTIM-18. LUMINOS-101: INITIAL SAFETY AND TOLERABILITY OF PVSRIPO AND PEMBROLIZUMAB COMBINATION THERAPY IN RECURRENT GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2021, 23, vi53-vi54.	1.2	1
20	CTIM-13. PHASE 1 CLINICAL TRIAL OF ONCOLYTIC VIRAL IMMUNOTHERAPY WITH CAN-2409 + VALACYCLOVIR IN COMBINATION WITH NIVOLUMAB AND STANDARD OF CARE (SOC) IN NEWLY DIAGNOSED HIGH-GRADE GLIOMA (HGG). <i>Neuro-Oncology</i> , 2021, 23, vi52-vi52.	1.2	1
21	RARE-11. EFFICACY AND SAFETY OF DABRAFENIB + TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E MUTATED LOW-GRADE GLIOMA (LGG). <i>Neuro-Oncology</i> , 2018, 20, vi238-vi239.	1.2	0
22	ATIM-32. PERSONALIZED NEOANTIGEN-TARGETING VACCINE GENERATES ROBUST SYSTEMIC AND INTRATUMORAL T CELL RESPONSES IN GLIOBLASTOMA (GBM) PATIENTS. <i>Neuro-Oncology</i> , 2018, 20, vi8-vi8.	1.2	0
23	A Novel Role for CpG Oligonucleotides in Tumor Immunotherapy: CpG-ODN Induce Targeted Chemokine-Induced Lymphocyte Migration to the Peripheral Tissues in Humans.. <i>Blood</i> , 2007, 110, 1791-1791.	1.4	0
24	PATH-16. EVALUATION OF SEX-BASED DIFFERENCES IN CLINICAL OUTCOMES AND TUMOR GENOMICS IN PATIENTS WITH NEWLY DIAGNOSED IDH-WILDTYPE GLIOBLASTOMA RECEIVING CHEMORADIATION. <i>Neuro-Oncology</i> , 2021, 23, vi118-vi118.	1.2	0
25	CTNI-40. EVALUATING FEASIBILITY AND EFFICIENCY OF PHASE II ADAPTIVE PLATFORM TRIAL DESIGNS BASED ON THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT) EXPERIENCE. <i>Neuro-Oncology</i> , 2021, 23, vi68-vi69.	1.2	0
26	CTIM-14. RANDOMIZED PHASE II OPEN LABEL STUDY OF NIVOLUMAB PLUS STANDARD DOSE BEVACIZUMAB VS NIVOLUMAB PLUS LOW DOSE BEVACIZUMAB IN RECURRENT GLIOBLASTOMA (RGM). NIVOLUMAB BENEFITS OLDER POPULATION. <i>Neuro-Oncology</i> , 2021, 23, vi52-vi52.	1.2	0
27	BIOM-30. BLOOD COUNTS THROUGH TREATMENT COURSE IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS RECEIVING CHEMORADIATION. <i>Neuro-Oncology</i> , 2021, 23, vi17-vi17.	1.2	0
28	NCOG-03. PREDICTORS OF NEUROLOGIC DEATH IN PATIENTS WITH BRAIN METASTASES. <i>Neuro-Oncology</i> , 2021, 23, vi152-vi152.	1.2	0
29	NIMG-33. VOLUMETRIC TUMOR MEASUREMENTS ARE SUPERIOR TO 2D BIDIRECTIONAL MEASUREMENTS IN THE EVALUATION OF IDH INHIBITION IN DIFFUSE GLIOMAS: EVIDENCE FROM A PROSPECTIVE PHASE I TRIAL OF IVOSIDENIB. <i>Neuro-Oncology</i> , 2021, 23, vi136-vi136.	1.2	0
30	NIMG-24. RANO CRITERIA DETECTS EARLY PROGRESSION SOONER THAN MODIFIED RANO CRITERIA IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2021, 23, vi133-vi133.	1.2	0
31	CTNI-54. A SINGLE ARM PHASE II STUDY OF THE DUAL MTORC1/MTORC2 INHIBITOR VISTUSERTIB PROVIDED FOR SPORADIC PATIENTS WITH GRADE II-III MENINGIOMAS THAT RECUR OR PROGRESS AFTER SURGERY AND RADIATION. <i>Neuro-Oncology</i> , 2021, 23, vi72-vi72.	1.2	0
32	INNV-40. REAL WORLD INTEGRATION OF THE NEUROLOGIC ASSESSMENT IN NEURO-ONCOLOGY (NANO) SCALE IN CLINICAL PRACTICE IN PATIENTS WITH IDH-WT GBM. <i>Neuro-Oncology</i> , 2021, 23, vi114-vi114.	1.2	0